Expression of p53, p21 and cyclin D1 in penile cancer: p53 predicts poor prognosis

Abstract

In patients with PC, the expression of p53 in the primary tumour specimen can be reproducibly assessed and is negatively associated with cancer specific survival.

Her2/neu expression in urothelial dysplasia, carcinoma in situ, and superficial urothelial carcinoma and its value in assessing the response to BCG therapy

“…The number of dysplastic cases examined was not sufficient to draw definitive conclusions in this regard. This result is similar to that obtained by Gunia et al (2011), who also reported that, from a therapeutic viewpoint, prospective clinical studies should investigate the potential benefit of Her2-targeted therapies in CIS, particularly in cases unresponsive to conventional therapeutic regimens.…”

“…However, its role in dysplasia and CIS has not been clarified (Latif et al, 2004;Hansel et al, 2008;Kolla et al, 2008;Laé et al, 2009). Gunia et al (2011) studied the so-far neglected diagnostic significance of Her2/neu protein expression profiles in flat lesions of the urinary bladder mucosa in terms of differentiating CIS from dysplasia. Moreover, Gunia et al (2011) reported heterogeneous Her2/neu expression within the mucosa under the non-CIS (dysplasia) condition.…”

Does the width of the surgical margin of safety or premalignant dermatoses at the negative surgical margin affect outcome in surgically treated penile cancer?

“…Our recently described cohort encompasses 92 consecutive patients surgically treated for PSC between January 1993 and December 2010 in six different German hospitals 6. All patients were clinically staged to be without metastasis (cM0) before surgery using CT, MRI or chest x-ray.…”

Inherent Grading Characteristics of Individual Pathologists Contribute to Clinically and Prognostically Relevant Interobserver Discordance Concerning Broders' Grading of Penile Squamous Cell Carcinomas

“…dynamic sentinel node biopsy or ultrasound-guided fine needle aspiration) suffer from false-negative rates, and none of the recently reported prognostic biomarkers has been implemented on a regular basis in clinical practice yet [10,17,18,19,20,21,22,23]. …”